Prosecution Insights
Last updated: November 04, 2026
Application No. 19/106,024

HALOGENATED SOMATOSTATIN ANALOGS WITH MULTIPLE SOMATOSTATIN RECEPTOR SUBTYPE SELECTIVITY

Non-Final OA §103
Filed
Feb 24, 2025
Priority
Aug 30, 2022 — provisional 63/373,945 +1 more
Examiner
CRAIG, KAILA ANGELIQUE
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Grafton Therapeutics Sàrl
OA Round
1 (Non-Final)
35%
Grant Probability
At Risk
1-2
OA Rounds
1y 11m
Est. Remaining
59%
With Interview

Examiner Intelligence

Grants only 35% of cases
35%
Career Allowance Rate
23 granted / 66 resolved
-25.2% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
44 currently pending
Career history
123
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
52.7%
+12.7% vs TC avg
§102
16.6%
-23.4% vs TC avg
§112
20.9%
-19.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 66 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Cancelled: 13, 14 Examined Herein: 1-12, 15-17 Priority Acknowledgment is made of applicant's claim for priority under based upon an application filed in PRO 63/373,945 on 8/30/2022 and PCT/EP2023/073801 on 8/30/2023. Information Disclosure Statement The information disclosure statement (IDS) submitted on 6/5/2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Drawings The drawings received on 2/24/2025 are accepted. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1, 4-12, 15, and 17 are rejected under 35 U.S.C. 103 as being unpatentable over Goodman (US 2007/0041902 A1, Published 2/22/2007), in view of Brown (Bioisosteres in Medicinal Chemistry, 2012, First Edition, Wiley-VCH Verlag GmbH & Co. KGaA). With respect to claim 1, Goodman discloses a compound of Formula I, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2, that binds selectively to SST2 and SST5. PNG media_image1.png 435 680 media_image1.png Greyscale [Structure retrieved from MedChemExpress, Cat. No.: HY-P2434, AP102, depicting (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 disclosed by Goodman. For illustration purposes only.] Wherein: X1 is -I; X2 is -I; and Y1 is -H. [Goodman, 0012, 0030] With respect to claim 4, Goodman discloses a compound of Formula I-A, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2, that binds selectively to SST2 and SST5; PNG media_image1.png 435 680 media_image1.png Greyscale [Structure retrieved from MedChemExpress, Cat. No.: HY-P2434, AP102, depicting (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 disclosed by Goodman. For illustration purposes only.] Wherein: X1 is -I; and X2 is -I. [Goodman, 0012, 0030] With respect to claim 12, Goodman discloses a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. [Goodman, 0051, 0056] With respect to claims 15 and 17, Goodman discloses a method of treating an SST2 and SST5 cell proliferative disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound. [Goodman, 0019-0021, 0032, 0033, 0035, 0040, 0043] Goodman does not disclose that X1 and X2 are not both -I. However, with respect to claims 1 and 4-11, Brown discloses that fluorine, chlorine, bromine, and iodine are bioisosteres. [Brown, Page 23, 2.4.5] Brown discloses that bioisosteres are functional groups that share similar physical or chemical properties and maintain similar activity. Brown further discloses that bioisosterism is used in the discovery and development of a candidate for clinical evaluation by making small modifications to a lead compound to improve properties, such as pharmacological activity, selectivity, and pharmacokinetics. [Brown, Page 15, Paragraph 1] Modifying the compound disclosed by Goodman by replacing X1 and/or X2 (each represented by iodine) with chlorine, bromine, and/or fluorine results in the compound of claim 1. More specifically: Modifying the compound disclosed by Goodman by replacing X2 (iodine) with chlorine, bromine, or fluorine results in the compound of claims 1, 4, 6 (compound 1), and/or 7, wherein X1 is -I and X2 is -F, -Cl, or -Br, such that X1 and X2 are not both -I. Modifying the compound disclosed by Goodman by replacing X1 (iodine) with chlorine results in the compound of claims 1, 4, 6 (compound 2), and/or 8, wherein X1 is -Cl and X2 is -I, such that X1 and X2 are not both -I. Modifying the compound disclosed by Goodman by replacing each of X1 and X2 (iodine) with chlorine results in the compound of claims 1, 4, 5, 6 (compound 3) and 9, wherein X1 is -Cl and X2 is -Cl. Modifying the compound disclosed by Goodman by replacing each of X1 and X2 (iodine) with fluorine results in the compound of claims 1, 4, 5, 6 (compound 4) and 10, wherein X1 is -F and X2 is -F. Modifying the compound disclosed by Goodman by replacing each of X1 and X2 (iodine) with bromine results in the compound of claims 1, 4, 5, 6 (compound 5) and 11, wherein X1 is -Br and X2 is -Br. It would be obvious to one of ordinary skill in the art to modify the compound disclosed by Goodman by replacing X1 and/or X2 (each represented by iodine) with chlorine, bromine, and/or fluorine and have a reasonable expectation of success. Goodman discloses a compound, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2, that binds selectively to SST2 and SST5, comprising substituents X1 and X2 each represented by iodine. Brown discloses that fluorine, chlorine, bromine, and iodine are bioisosteres of each other, that is, functional groups that share similar physical or chemical properties and maintain similar activity. Brown further discloses that bioisosterism is used in the discovery and development of a candidate for clinical evaluation, involving small modifications to a lead compound to improve its properties. Accordingly, the combined teachings of Goodman and Brown reasonably suggest that X1 and/or X2 (each represented by iodine) in the compound disclosed by Goodman may be replaced with their bioisosteres fluorine, chlorine, and/or bromine. One would have been motivated to do so because a prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities, with the expectation that compounds similar in structure will have similar properties. MPEP 2144.09(I). Moreover, claimed and prior art compounds are expected to have similar activity when the structural difference between the compounds involves a known bioisosteric replacement. MPEP 2144.09(III). Therefore, one would have been motivated to replace X1 and/or X2 (iodine) with chlorine, bromine, and/or fluorine because the halogens are bioisosteres of each other, and the modified compound suggested by Goodman and Brown would be expected to have activity similar to the compound disclosed by Goodman. Claims 1-3, 5-12, and 15-17 are rejected under 35 U.S.C. 103 as being unpatentable over Mansi (Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5, Molecules, 9/11/2020, 25(18): 4155), in view of Brown. With respect to claim 1, Mansi discloses a compound of Formula I, DOTA-ST8950, that binds selectively to SST2 and SST5; PNG media_image2.png 531 819 media_image2.png Greyscale [Mansi, Page 3, Figure 1] Wherein: X1 is -I; X2 is -I; and Y1 is a chelator. [Mansi, Page 3, Figure 1] With respect to claim 2, Mansi discloses that Y1 is a chelator. [Mansi, Page 3, Figure 1] With respect to claims 3 and 16, Mansi discloses that the chelator is complexed to the radionuclide 177Lu. [Mansi, Page 3, Figure 1] With respect to claim 12, Mansi discloses a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, sodium acetate buffer. [Mansi, Page 11, 3.1] With respect to claims 15 and 17, Mansi discloses a method of treating an SST2 and SST5 cell proliferative disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound. [Mansi, Page 11, 3.5.1-3.5.3] Mansi does not disclose that X1 and X2 are not both -I. However, with respect to claims 1 and 5-11, Brown discloses that fluorine, chlorine, bromine, and iodine are bioisosteres. [Brown, Page 23, 2.4.5] Brown discloses that bioisosteres are functional groups that share similar physical or chemical properties and maintain similar activity. Brown further discloses that bioisosterism is used in the discovery and development process of a candidate for clinical evaluation by making small modifications to a lead compound to improve properties such as pharmacological activity, selectivity, and pharmacokinetics. [Brown, Page 15, Paragraph 1] Modifying the compound disclosed by Mansi by replacing X1 and/or X2 (each represented by iodine) with chlorine, bromine, and/or fluorine results in the compound of claim 1. More specifically: Modifying the compound disclosed by Mansi by replacing X2 (iodine) with chlorine, bromine, or fluorine results in the compound of claims 1, 6 (compound 1), and/or 7, wherein X1 is -I and X2 is -F, -Cl, or -Br, such that X1 and X2 are not both -I. Modifying the compound disclosed by Mansi by replacing X1 (iodine) with chlorine results in the compound of claims 1, 6 (compound 2), and/or 8, wherein X1 is -Cl and X2 is -I, such that X1 and X2 are not both -I. Modifying the compound disclosed by Mansi by replacing each of X1 and X2 (iodine) with chlorine results in the compound of claims 1, 5, 6 (compound 3) and 9, wherein X1 is -Cl and X2 is -Cl. Modifying the compound disclosed by Mansi by replacing each of X1 and X2 (iodine) with fluorine results in the compound of claims 1, 5, 6 (compound 4) and 10, wherein X1 is -F and X2 is -F. Modifying the compound disclosed by Mansi by replacing each of X1 and X2 (iodine) with bromine results in the compound of claims 1, 5, 6 (compound 5) and 11, wherein X1 is -Br and X2 is -Br. It would be obvious to one of ordinary skill in the art to modify the compound disclosed by Mansi by replacing X1 and/or X2 (each represented by iodine) with chlorine, bromine, and/or fluorine and have a reasonable expectation of success. Mansi discloses a compound, DOTA-ST8950, that binds selectively to SST2 and SST5 comprising substituents X1 and X2 each represented by iodine. Brown discloses that fluorine, chlorine, bromine, and iodine are bioisosteres of each other, that is, functional groups that share similar physical or chemical properties and maintain similar activity. Brown further discloses that bioisosterism is used in the discovery and development of a candidate for clinical evaluation, involving small modifications to a lead compound to improve its properties. Accordingly, the combined teachings of Mansi and Brown reasonably suggest that X1 and X2 (each represented by iodine) in the compound disclosed by Mansi may be replaced with their bioisosteres fluorine, chlorine, and/or bromine. One would have been motivated to do so because a prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities, with the expectation that compounds similar in structure will have similar properties. MPEP 2144.09(I). Moreover, claimed and prior art compounds are expected to have similar activity when the structural difference between the compounds involves a known bioisosteric replacement. MPEP 2144.09(III). Therefore, one would have been motivated to replace X1 and/or X2 (iodine) with chlorine, bromine, and/or fluorine because the halogens are bioisosteres of each other, and the modified compound suggested by Mansi and Brown would be expected to have activity similar to the compound disclosed by Mansi. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAILA A CRAIG whose telephone number is (703)756-4540. The examiner can normally be reached Monday-Friday 0800-1600. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /K.A.C./Examiner, Art Unit 1618 /Michael G. Hartley/Supervisory Patent Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Feb 24, 2025
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12752023
Near-Infrared Dyes And Conjugates For Targeting Tumors
1y 0m to grant Granted Oct 06, 2026
Patent 12629431
NANOPARTICLES WITH TUNABLE AFTERGLOW AND COMPOSITIONS AND METHODS THEREOF
4y 8m to grant Granted May 19, 2026
Patent 12630573
HIGH-AFFINITY CU(I) LIGANDS AND METHODS OF USE THEREOF
4y 7m to grant Granted May 19, 2026
Patent 12527732
BIOBASED POLYGLYCERYL ESTERS AND COMPOSITIONS COMPRISING THE SAME
3y 3m to grant Granted Jan 20, 2026
Patent 12496262
Jammed Emulsion Toothpaste Compositions
3y 3m to grant Granted Dec 16, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
35%
Grant Probability
59%
With Interview (+24.0%)
3y 7m (~1y 11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 66 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month